within Pharmacolibrary.Drugs.ATC.J;

model J05AP03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.35,
    Cl             = 0.0002733333333333333,
    adminDuration  = 600,
    adminMass      = 800 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.193,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 10.020000000000001
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J05AP03</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Boceprevir is a direct-acting antiviral drug that inhibits the NS3/4A serine protease of hepatitis C virus (HCV). It was used in combination with other antiviral drugs (such as peginterferon alfa and ribavirin) for the treatment of chronic HCV infection, specifically genotype 1. Boceprevir was approved by the FDA in 2011 but has been discontinued and is no longer marketed due to newer, more effective HCV medications with better safety profiles.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics reported for healthy adult subjects (both sexes), after multiple oral doses of 800 mg three times daily.</p><h4>References</h4><ol><li><p>Treitel, M, Marbury, T, Preston, RA, Triantafyllou, I, Feely, W, O&#x27;Mara, E, Kasserra, C, Gupta, S, &amp; Hughes, EA (2012). Single-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal function. <i>Clinical pharmacokinetics</i> 51(9) 619–628. DOI:<a href=&quot;https://doi.org/10.1007/BF03261935&quot;>10.1007/BF03261935</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/22799589/&quot;>https://pubmed.ncbi.nlm.nih.gov/22799589</a></p></li><li><p>Jiang, X, Su, H, Shang, W, Zhou, F, Zhang, Y, Zhao, W, Zhang, Q, Xie, H, Jiang, L, Nie, T, Yang, F, Xiong, M, Huang, X, Li, M, Chen, P, Peng, S, Xiao, G, Jiang, H, Tang, R, …, &amp; Xu, Y (2023). Structure-based development and preclinical evaluation of the SARS-CoV-2 3C-like protease inhibitor simnotrelvir. <i>Nature communications</i> 14(1) 6463–None. DOI:<a href=&quot;https://doi.org/10.1038/s41467-023-42102-y&quot;>10.1038/s41467-023-42102-y</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37833261/&quot;>https://pubmed.ncbi.nlm.nih.gov/37833261</a></p></li><li><p>Foote, BS, Spooner, LM, &amp; Belliveau, PP (2011). Boceprevir: a protease inhibitor for the treatment of chronic hepatitis C. <i>The Annals of pharmacotherapy</i> 45(9) 1085–1093. DOI:<a href=&quot;https://doi.org/10.1345/aph.1P744&quot;>10.1345/aph.1P744</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/21828346/&quot;>https://pubmed.ncbi.nlm.nih.gov/21828346</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J05AP03;
